![]() |
市場調查報告書
商品編碼
2177774
多核苷酸護膚品市場預測至2034年-全球產品類型、產品形態、應用、通路、最終用戶、膚質和區域分析Polynucleotide Skincare Products Market Forecasts to 2034 - Global Analysis By Product Type, Product Form, Application, Distribution Channel, End User, Skin Type and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球多核苷酸護膚品市場規模將達到 4 億美元,並在預測期內以 12.1% 的複合年成長率成長,到 2034 年將達到 10 億美元。
多核苷酸護膚品是含有源自海洋或生物技術的核酸片段的局部用製劑,能夠幫助肌膚保濕、維持屏障功能並顯著改善膚質。這些製劑包含聚脫氧核苷酸、短鏈多核苷酸和高分子量多核苷酸的混合物,被認為可以形成保濕屏障並促進肌膚的修復過程。它們以精華液、乳霜、乳液、凝膠和面膜等形式配製而成,適用於日常護理和術後護理,適合所有膚質,包括乾性、油性和混合性肌膚。
治療後復原的需求
隨著雷射、微針和化學換膚等美容療程的日益普及,人們對能夠減輕不適感並促進皮膚屏障功能恢復的修復性外用製劑的需求也日益成長。多核苷酸製劑被定位為術後護理產品,能夠舒緩和滋潤受損肌膚,符合診所的治療方案。皮膚科醫生和美容師推薦使用專業的修復護理產品,而這種專業支援也推高了產品的定價。隨著亞太地區和北美地區美容療程數量的增加,對修復性多核苷酸產品的需求也隨之增加。
缺乏獨立證據
支持多核苷酸護膚的臨床證據仍集中在廠商資助的研究中,這限制了尋求獨立檢驗的皮膚科醫師的接受度。消費者越來越傾向於參考評論,質疑外用核苷酸鏈與成熟的保濕成分和胜肽類相比是否具有可衡量的效果。由於缺乏可靠的對比試驗,品牌難以在一般通路中為其高價定價提供基礎。這種證據的匱乏減緩了多核苷酸護膚品在早期診所之外的推廣速度,並限制了其在主流零售管道的擴張。
從診所到居家護理
醫療美容中心和皮膚科診所為多核苷酸品牌提供了一條天然途徑,使其能夠將專業護理延伸至居家護理產品。在診所接受治療的患者通常樂於接受診所外帶精華液和乳霜,以維持治療效果,比單純的零售通路具有更高的轉換率和復購率。將居家護理套裝作為治療套餐的一部分進行銷售,可以增加診所的收入並提高患者留存率。隨著美容治療服務提供者尋求提供差異化的零售產品,與診所通路的合作可以加速品牌在整個高階市場的成長。
再生護膚市場競爭異常激烈。
再生護膚市場充斥著各種活性成分,例如外泌體、胜肽、生長因子模擬物和多聚核苷酸(PDRN),它們都聲稱能夠改善皮膚屏障功能和膚質。消費者面臨琳瑯滿目的選擇,品牌也難以將多聚核苷酸與其他行銷訊息相似的相關技術區分開來。如果各大公司統一訊息已建立的活性成分,多聚核苷酸產品可能會被視為可以互換。因此,每個品牌都必須建立清晰的技術標誌和臨床支持,才能保住貨架空間和價格優勢。
疫情擾亂了美容診所的運營,並推遲了專業產品的上市,限制了多核苷酸產品透過治療管道的早期推廣。疫情期間,消費者轉向居家護膚,並在網路上搜尋以修復為重點的成分,這促進了零售市場的早期試用。疫情過後,隨著治療數量的恢復和診所零售項目的擴張,需求也隨之復甦。同時,各大品牌加強了電商分銷體系和臨床支持,以鞏固其在市場上的高階定位。
在預測期內,聚脫氧核苷酸混合物細分市場預計將佔據最大的市場佔有率。
由於其臨床應用廣泛、耐受性良好,且與術後恢復方案高度相關,預計在預測期內,聚脫氧核苷酸混合物將佔據最大的市場佔有率。皮膚科醫生和醫療美容機構推薦使用這些混合物來舒緩敏感肌膚並促進屏障功能的修復,這已獲得專業人士的認可。隨著亞太和北美地區治療量的不斷成長,聚脫氧核苷酸製劑仍然是主流成分,從而保持了其領先的銷售佔有率。
預計在預測期內,「血清」細分市場將呈現最高的複合年成長率。
在預測期內,精華液細分市場預計將呈現最高的成長率,這主要得益於消費者對質地輕盈、易於吸收且可與修復護理和日常護膚疊加使用的產品的偏好。精華液非常適合診所和專業零售管道,品牌可以利用這些管道以高階價格突出其多核苷酸濃度和臨床定位。隨著配方研發人員不斷改進產品的穩定性和質地,預計品牌自有電商平台和專業通路將迎來精華液新品上市的高峰,使其成為成長最快的產品類別。
在整個預測期內,北美預計將保持最大的市場佔有率,這得益於其成熟的醫療美容基礎設施、較高的單次治療費用以及消費者對再生護膚程序的強烈親和性。美國是區域銷售的主要驅動力,這得益於皮膚科診所和醫療水療中心推薦術後居家護理,以及銷售高階精華液的專業零售商。對再生護膚品牌的大力投資和嚴格的臨床驗證標準進一步鞏固了該地區的領先地位。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於醫療美容的快速發展、成熟的多步驟護膚流程,以及韓國、中國、日本和印度強勁的優質化趨勢。該地區的消費者積極採用與治療相關的修復產品,而當地製造商也在擴大多核苷酸成分的供應並與診所建立合作關係。電子商務的蓬勃發展和醫美診所網路的不斷擴展進一步提升了產品的可及性,使亞太地區成為成長最快的區域市場。
北美洲
我們
加拿大
墨西哥
歐洲
英國
德國
法國
義大利
西班牙
荷蘭
比利時
瑞典
瑞士
波蘭
其他歐洲國家
亞太地區
中國
日本
印度
韓國
澳洲
印尼
泰國
馬來西亞
新加坡
越南
亞太其他地區
南美洲
巴西
阿根廷
哥倫比亞
智利
秘魯
南美洲其他地區
世界其他地區(RoW)
中東
沙烏地阿拉伯
阿拉伯聯合大公國
卡達
以色列
其他中東國家
非洲
南非
埃及
摩洛哥
其他非洲國家
企業概況
對其他市場參與者(最多 3 家公司)進行全面分析
對主要公司進行SWOT分析(最多3家公司)
區域細分
根據客戶要求,我們可以提供主要國家的市場估算和預測,以及複合年成長率(註:需經可行性確認)。
競爭性標竿分析
According to Stratistics MRC, the Global Polynucleotide Skincare Products Market is accounted for $0.4 billion in 2026 and is expected to reach $1.0 billion by 2034 growing at a CAGR of 12.1% during the forecast period. Polynucleotide skincare products are topical formulations that incorporate fragmented nucleic acid chains derived from marine or biotechnological sources to support skin hydration, barrier comfort, and visible texture refinement. These preparations contain polydeoxyribonucleotide, short-chain, and high-molecular-weight polynucleotide blends that form moisture-retaining films and are believed to support the skin's recovery processes. They are formulated into serums, creams, lotions, gels, and masks for daily use or post-procedure care across dry, oily, and combination skin types.
Post-Procedure Recovery Demand
Rising volumes of aesthetic procedures such as lasers, microneedling, and chemical peels are driving demand for recovery-focused topical formulations that reduce discomfort and support barrier restoration. Polynucleotide preparations are positioned as post-procedure care that calms reactive skin while maintaining hydration, which aligns with clinic protocols. Dermatologists and aestheticians recommend dedicated recovery regimens, creating professional endorsement that supports premium pricing. As procedure volumes grow in Asia Pacific and North America, demand for recovery-positioned polynucleotide products expands accordingly.
Limited Independent Evidence
Clinical evidence supporting polynucleotide skincare remains concentrated in manufacturer-sponsored studies, which limits acceptance among dermatologists who require independent validation. Review-driven consumers increasingly question whether topical nucleic acid chains deliver measurable benefit compared with established hydrators and peptides. Without robust comparative trials, brands struggle to justify premium pricing in mass channels. This evidence gap slows adoption beyond early-adopter clinics and constrains expansion into mainstream retail assortments.
Clinic-to-Home Regimen Extension
Medical spas and dermatology clinics offer a natural pathway for polynucleotide brands to extend professional treatments into home-care regimens. Patients who receive in-clinic procedures are receptive to take-home serums and creams that maintain results, creating higher conversion and repeat purchase than purely retail launches. Bundling home-care kits with procedure packages improves clinic revenue and patient adherence. As aesthetic providers seek differentiated retail offerings, clinic-channel partnerships can accelerate brand growth across premium segments.
Crowded Regenerative Positioning
The regenerative skincare space is crowded with competing actives such as exosomes, peptides, growth factor mimics, and PDRN, each claiming barrier and texture benefits. Buyers face confusing choices, and brands struggle to differentiate polynucleotides from adjacent technologies with similar marketing narratives. If larger companies consolidate messaging around established actives, polynucleotide products may be perceived as interchangeable. Consequently, brands must build clear technical identity and clinical substantiation to defend shelf space and pricing.
The pandemic disrupted aesthetic clinic operations and delayed professional launches, which limited early polynucleotide adoption through procedure-linked channels. During the crisis, consumers invested in at-home regimens and researched recovery-focused ingredients online, supporting early retail trial. Post-pandemic, returning procedure volumes and expanded clinic retail programs have revived demand, while brands strengthened e-commerce distribution and clinical substantiation to support premium positioning across markets.
The Polydeoxyribonucleotide Blends segment is expected to be the largest during the forecast period
The Polydeoxyribonucleotide Blends segment is expected to account for the largest market share during the forecast period, due to their established clinical familiarity, favorable tolerability profile, and strong association with post-procedure recovery protocols. Dermatologists and medical spas recommend these blends for calming reactive skin and supporting barrier restoration, which builds professional endorsement. As procedure volumes grow across Asia Pacific and North America, polydeoxyribonucleotide formulations remain the mainstream ingredient base, thereby sustaining leading revenue share.
The Serums segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Serums segment is predicted to witness the highest growth rate, driven by consumer preference for lightweight, fast-absorbing formats that layer easily within recovery and daily routines. Serums allow brands to highlight polynucleotide concentration and clinical positioning at premium price points, which suits clinic and specialty retail channels. As formulators improve stability and texture, serum launches multiply across brand-owned e-commerce and professional channels, making this the fastest-growing product form.
During the forecast period, the North America region is expected to hold the largest market share, due to mature medical aesthetics infrastructure, high per-procedure spending, and strong consumer familiarity with recovery-focused regimens. The United States dominates regional revenue, supported by dermatology clinics and medical spas that recommend take-home post-procedure care, alongside specialty retailers carrying premium serums. Active investment in regenerative skincare brands and robust clinical substantiation standards further reinforce the region's leading position.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapid medical aesthetics expansion, deeply embedded multi-step skincare routines, and strong premiumization across South Korea, China, Japan, and India. Consumers in the region readily adopt procedure-linked recovery products, while local manufacturers scale polynucleotide ingredient supply and clinic partnerships. Expanding e-commerce and aesthetic clinic networks further support availability, making Asia Pacific the fastest-growing regional market.
Key players in the market
Some of the key players in Polynucleotide Skincare Products Market include L'Oreal S.A., The Estee Lauder Companies Inc., Beiersdorf AG, Shiseido Company, Limited, Unilever PLC, The Procter & Gamble Company, Kao Corporation, Kenvue Inc., Amorepacific Corporation, LG H&H Co., Ltd., Coty Inc., Natura &Co, Edgewell Personal Care Company, Galderma Group AG, Pierre Fabre Laboratories, and Rohto Pharmaceutical Co., Ltd.
In October 2026, LG H&H Co., Ltd. launched a polydeoxyribonucleotide recovery serum formulated for post-procedure barrier comfort, supported by clinic education programs and distributed through medical spa channels and brand-owned e-commerce across South Korea and Japan.
In September 2026, Galderma Group AG expanded its post-procedure skincare portfolio with short-chain polynucleotide creams designed for skin texture and hydration, targeting dermatology clinics and professional aestheticians across European and North American markets.
In August 2026, Kao Corporation introduced high-molecular-weight polynucleotide masks and gels positioned for visible radiance and barrier comfort, distributed through specialty retailers and online marketplaces across Japan and Southeast Asia.
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Netherlands
Belgium
Sweden
Switzerland
Poland
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Thailand
Malaysia
Singapore
Vietnam
Rest of Asia Pacific
South America
Brazil
Argentina
Colombia
Chile
Peru
Rest of South America
Rest of the World (RoW)
Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
Africa
South Africa
Egypt
Morocco
Rest of Africa
Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.